Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Schlieren

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43892   clinical trials with a EudraCT protocol, of which   7299   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    22 result(s) found for: Schlieren. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2005-000727-42 Sponsor Protocol Number: CYT004-MelQbG10 01 Start Date*: 2006-01-20
    Sponsor Name:Cytos Biotechnology AG
    Full Title: A Phase IIa Study to Evaluate Safety, Tolerability, and Immunogenicity of a Melan-A-VLP Vaccine in HLA-A2 Positive Patients with stage III/IV Malignant Melanoma
    Medical condition: Patients with Stage III/IV Malignant Melanoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-001885-41 Sponsor Protocol Number: DLX105-003-002-001 Start Date*: 2013-07-11
    Sponsor Name:Delenex Therapeutics AG
    Full Title: A multi-center, double-blinded, randomized, placebo-controlled, phase II study to evaluate the safety, tolerability and efficacy of a topical application of DLX105 onto lesional skin in patients wi...
    Medical condition: mild-to-moderate plaque-type psoriasis vulgaris 6 (PASI ≤15)
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004858 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-000890-10 Sponsor Protocol Number: MP0420-CP302 Start Date*: 2021-05-03
    Sponsor Name:Molecular Partners AG
    Full Title: A randomized, double-blind, placebo-controlled, multicenter study of ensovibep (MP0420) in ambulatory adult patients with symptomatic COVID-19
    Medical condition: Symptomatic COVID-19 in ambulatory patients
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004862 10084401 COVID-19 respiratory infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-003070-39 Sponsor Protocol Number: CYT003-QbG1012 Start Date*: 2012-11-26
    Sponsor Name:Cytos Biotechnology AG
    Full Title: A Randomized, Placebo-Controlled, Phase IIb Dose-Finding Study of CYT003-QbG10, a TLR9-Agonist, in Patients with Moderate to Severe Allergic Asthma not Sufficiently Controlled on Current Standard T...
    Medical condition: Allergic Asthma
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004855 10001705 Allergic asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) DE (Prematurely Ended) CZ (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-004639-39 Sponsor Protocol Number: CYT003-QbG10 09 Start Date*: 2008-10-03
    Sponsor Name:Cytos Biotechnology AG
    Full Title: Double-blind, Placebo-controlled Dose-finding Study with CYT003-QbG10 in Adult Patients with Rhinoconjunctivitis due to House Dust Mite Allergy.
    Medical condition: Adult patients with perennial allergic rhinoconjunctivitis due to house dust mite
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039097 Rhinoconjunctivitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: EE (Completed) DE (Completed) LV (Completed) LT (Completed) GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-003516-62 Sponsor Protocol Number: CYT003-QbG10 08 Start Date*: 2007-10-19
    Sponsor Name:Cytos Biotechnology AG
    Full Title: Double-blind, Placebo-controlled Study to Investigate an Immunomodulatory Therapy (CYT003-QbG10) in Adult Patients with Perennial Allergic Rhinoconjunctivitis.
    Medical condition: Adult patients with perennial allergic rhinoconjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039097 Rhinoconjunctivitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: EE (Completed) LT (Completed) LV (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002461-21 Sponsor Protocol Number: TBRU-dS-BC-PIIb Start Date*: 2018-10-29
    Sponsor Name:CUTISS AG
    Full Title: A Phase IIb, prospective, intra-patient randomised controlled, multicentre study to evaluate the safety and efficacy of an autologous bio-engineered dermo-epidermal skin substitute (EHSG-KF) for th...
    Medical condition: Children with partial deep dermal and full thickness burns
    Disease:
    Population Age: Newborns, Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: NL (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-002462-41 Sponsor Protocol Number: TBRU-dS-RAC-PII Start Date*: 2018-10-29
    Sponsor Name:CUTISS AG
    Full Title: A Phase II, prospective, intra-patient randomized controlled, multicentre study to evaluate the safety and efficacy of an autologous bio-engineered dermo-epidermal skin substitute (EHSG-KF) for the...
    Medical condition: Adults and children with full thickness skin defects
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-002460-41 Sponsor Protocol Number: TBRU-dS-BA-PIIb Start Date*: 2018-10-29
    Sponsor Name:CUTISS AG
    Full Title: A Phase IIb, prospective, intra-patient randomised controlled, multicentre study to evaluate the safety and efficacy of an autologous bio-engineered dermo-epidermal skin substitute (EHSG-KF) for th...
    Medical condition: Adults and adolescents with partial deep dermal and full thickness burns
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-006927-29 Sponsor Protocol Number: CYT003-QbG10 11 Start Date*: 2009-04-02
    Sponsor Name:Cytos Biotechnology AG
    Full Title: A Double-blind, Placebo-controlled Study to Assess Pharmacodynamic and Clinical Efficacy of CYT003-QbG10 in Patients with Persistent Allergic Asthma Bronchiale
    Medical condition: Adult Patients with Persistent Allergic Asthma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001705 Allergic asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-000365-33 Sponsor Protocol Number: CHDR2043 Start Date*: 2021-03-17
    Sponsor Name:Molecular Partners AG
    Full Title: A Phase 2a open label, non-comparative, single dose escalation study to evaluate the dynamics of viral clearance, pharmacokinetics and tolerability of ensovibep in patients with symptomatic COVID-1...
    Medical condition: SARS-CoV-2 infection (COVID-19)
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10084268 COVID-19 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2008-004862-24 Sponsor Protocol Number: ESBA105CRD04 Start Date*: 2009-01-02
    Sponsor Name:ESBATech, an Alcon Biomedical Research Unit LLC
    Full Title: An open-label exploratory study to assess the safety, tolerability and clinical activity of topically applied ESBA105 in patients with acute anterior uveitis
    Medical condition: Acute, unilateral anterior uveitis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10002709 Anterior uveitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-000801-28 Sponsor Protocol Number: MSB-IG-H-2101 Start Date*: 2023-07-24
    Sponsor Name:Cellerys AG
    Full Title: Multicenter, Phase Ib/IIa Study on the Safety and Efficacy of Autologous Peptide-coupled Red Blood Cells in Patients with Relapsing Remitting Multiple Sclerosis
    Medical condition: Relapsing Remitting Multiple Sclerosis (RRMS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Ongoing) CZ (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-002771-10 Sponsor Protocol Number: MP0250-CP201 Start Date*: 2017-03-27
    Sponsor Name:Molecular Partners AG
    Full Title: A Phase II open-label, single-arm, multicenter trial of MP0250 plus bortezomib+dexamethasone in patients with refractory and relapsed multiple myeloma
    Medical condition: Multiple myeloma (MM) is a relatively rare (114 000 new cases worldwide in 2012, i.e. 0.8% of total cancer cases [Cancer Research UK Incidence Statistics 2016]) blood cancer for which there is no c...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed) DK (Completed) AT (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2008-007012-15 Sponsor Protocol Number: CYT013-IL1bQb 01 Start Date*: 2009-05-28
    Sponsor Name:Cytos Biotechnology AG
    Full Title: A Two-Stage Randomized Placebo-controlled Ascending Dose Phase I/ IIa Study to Evaluate Safety, Tolerability, Pharmacodynamic Effects and Preliminary Efficacy of an Anti-Interleukin 1 beta Vaccine ...
    Medical condition: adult patients with type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012601 Diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-005843-93 Sponsor Protocol Number: CYT006-AngQb 02 Start Date*: 2008-02-21
    Sponsor Name:Cytos Biotechnology AG
    Full Title: A Double Blind, Randomized, Placebo Controlled, Parallel Group Phase IIa Study to Evaluate Safety and Tolerability, Pharmacodynamic Effects and Exploratory Efficacy of an Anti-Angiotensin II Vaccin...
    Medical condition: Mild to moderate essential hypertension
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020772 Hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-003454-29 Sponsor Protocol Number: CYT005-AllQbG10 04 Start Date*: 2007-10-19
    Sponsor Name:Cytos Biotechnology AG
    Full Title: Double-blind, Placebo-controlled Study to Investigate Safety, Tolerability, Immunogenicity and Clinical Efficacy of a Specific Immuotherapy Combining Allergen with CYT003-QbG10 (CYT005-AllQbG10) in...
    Medical condition: Adult patients with perennial allergic rhinoconjunctivitis due to house dust mite allergy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063527 Allergic respiratory symptom LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-007516-28 Sponsor Protocol Number: CYT006-AngQb 03 Start Date*: 2008-06-06
    Sponsor Name:Cytos Biotechnology AG
    Full Title: A Double Blind, Randomized, Placebo Controlled, Parallel Group, Dose-Titration Phase II Study to Evaluate Safety and Tolerability, Pharmacodynamic Effects and Efficacy of an Anti-Angiotensin II Vac...
    Medical condition: Mild to moderate essential hypertension
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020772 Hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-001712-21 Sponsor Protocol Number: ESBA105CRD02 Start Date*: 2009-03-05
    Sponsor Name:Delenex Therapeutics AG
    Full Title: A double-blind, randomised placebo-controlled Phase I/IIa study to investigate the safety, tolerability and efficacy on pain of intra-articular ESBA105 applied to patients with severely painful os...
    Medical condition: Osteoarthritis of the knee
    Disease: Version SOC Term Classification Code Term Level
    9.1 10031165 Osteoarthritis knee LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-005090-26 Sponsor Protocol Number: Kleb4V01 Start Date*: 2021-06-21
    Sponsor Name:LimmaTech Biologics AG
    Full Title: Safety and immunogenicity of a Klebsiella pneumoniae tetravalent bioconjugate vaccine (Kleb4V) administered to healthy adults: A FTIH phase I/II randomized and controlled study.
    Medical condition: Klebsiella pneumoniae (K. pneumoniae), a gram negative Enterobacteriaceae, is an opportunistic pathogen leading to hospital- and community-acquired infections (urinary tract infections, pneumonia a...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10046859 Vaccination LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 29 16:18:49 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA